Picture of Biovaxys Technology logo

BIOV — Biovaxys Technology Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-9.92%
3m-2.61%
6m-44.7%
1yr-47.46%
Volume Change (%)
10d/3m-50.68%
Price vs... (%)
52w High-82.31%
50d MA-9.31%
200d MA-49.96%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-85.26%
Return on Equity-78.98%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Oct 202231st Oct 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biovaxys Technology EPS forecast chart

Profile Summary

BioVaxys Technology Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is using its haptenized antigen technology platforms to develop vaccines to treat viral infections, such as SARS-CoV-2, human papillomavirus (HPV) and cancers, such as late-stage ovarian cancer, cervical cancer and melanoma. Its product portfolio includes BVX-0320, BVX-0121, BVX-0204, BVX-0918A, BVX-0918C, CoviDTH and Papilocare. BVX-0320 is an investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2. The vaccine is the recombinant S1 subunit of the spike protein of SARS-CoV-2 that has been modified with a chemical called hapten, specifically, dinitrophenyl (DNP). Its CoviDTH is a disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2. BVX-0918A is a haptenized tumor cell vaccine for ovarian cancer.

Directors

Last Annual
October 31st, 2021
Last Interim
January 31st, 2022
Incorporated
April 25th, 2018
Public Since
November 21st, 2018
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
92,338,681
Blurred out image of a map
Address
503 - 905 West Pender Street, VANCOUVER, V6C 1L6
Web
https://biovaxys.com/
Phone
+1 6042628835
Auditors
Dale Matheson Carr-Hilton LaBonte LLP

BIOV Share Price Performance

Upcoming Events for BIOV

Similar to BIOV

Picture of Albert Labs International logo

Albert Labs International

ca flag iconCanadian Securities Exchange

Picture of Algernon Pharmaceuticals logo

Algernon Pharmaceuticals

ca flag iconCanadian Securities Exchange

Picture of Asep Medical Holdings logo

Asep Medical Holdings

ca flag iconCanadian Securities Exchange

Picture of Avisa Diagnostics logo

Avisa Diagnostics

ca flag iconCanadian Securities Exchange

Picture of BetterLife Pharma logo

BetterLife Pharma

ca flag iconCanadian Securities Exchange

FAQ

Or unlock with your email

Or unlock with your email